To this end, NSCLC with high mutation burden and a smoking-associated trinucleotide signature were found to display more favorable and durable responses to the immune checkpoint inhibitor pembrolizumab targeting programmed cell death-1 (PD-1) [4]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.